Why the study?
Does Iloprost improve platelet preservation or protect the central nervous system in patients undergoing elective coronary surgery with cardiopulmonary bypass?
Does Iloprost improve platelet preservation or protect the central nervous system in patients undergoing elective coronary surgery with cardiopulmonary bypass?
Iloprost administration during cardiopulmonary bypass did not improve platelet preservation or CNS protection and was associated with unacceptable hypotension, leading to early trial termination.
Answers are grounded in this paper and cite their sources.
Iloprost confers no platelet or CNS protection during CPB and causes unacceptable hypotension; discourages use and closes this research avenue.
Twenty patients undergoing elective coronary surgery were randomized to receive either the prostacyclin analogue Iloprost (Zk 36374) 5 ng/kg/min for 30 minutes before cardiopulmonary bypass (CPB) increasing to 10 ng/kg/min during CPB, or placebo, to investigate any beneficial effect on platelet preservation, or protection of the central nervous system during clinical CPB. Originally 50 patients were to have entered the trial, but unacceptable hypotensive effects occu rred in five patients who received Iloprost, lead i ng to early data analysis. No significant improvement in platelet number, volume or function; bleeding time; arterial line filter δ dry weight; retinal microembolism; or neuropsychological function, attributable to Iloprost, could be identified. The role and optimal dose of Iloprost in clinical CPB remains to be established.
No takes yet. Share an insight, caveat, or question.
Blauth et al. (1987) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: